R&D channel feed – Endpoints News

R&D channel feed

Tempest Therapeutics’ triple combo shows promise in first-line liver cancer, stock jumps

3 years ago

Amgen bows out of PhIIb trials testing bispecific, fusion protein for lupus

3 years ago

Astellas, Supernus and Patrick Dempsey take the stage at Publicis Health Media’s HealthFront

3 years ago

Celularity ends clinical trial, to now focus on new NK cell therapy amid cash crunch

3 years ago

Sanofi scraps topical BTK drug from $3.7B Principia buyout

3 years ago

Eli Lilly showcases PhIII weight loss data for type 2 diabetes patients taking tirzepatide

3 years ago

AstraZeneca cuts Alexion's PhIII Wilson disease drug, takes $244M writedown

3 years ago

Early results from Alzheimer’s study set stage for Alnylam’s expansion into brain diseases

3 years ago

Following CRL, Form 483 reveals more quality issues at Alvotech’s production facility in Iceland

3 years ago

After a patient death in NKT trial, Athenex hires chief restructuring officer

3 years ago

Novartis' PNH drug succeeds in PhIII and will go to FDA, setting up battle with AstraZeneca

3 years ago

Evelo again misses primary goal in atopic dermatitis and will shutter study, lay off more staff

3 years ago

South Dakota-based Covid-19 transgenic cow antibody startup claims its first PhIII win

3 years ago

GSK ends PhIII Zejula trial after running into challenges enrolling patients

3 years ago

Roche's Q1 pipeline cleanup claims PhII myelofibrosis drug, early-stage MAGE-A4 work

3 years ago

With proxy fight deadline a month away, Illumina announces plans to cut $100M in costs

3 years ago

Biogen CEO in search for 'external growth' to boost pipeline as revenue falls

3 years ago

MarketingRx roundup: HHS' Covid campaign continues as health emergency end nears; Pharmas celebrate Earth Day

3 years ago

Ideaya goes forward with $150M offering after touting PhII cancer data

3 years ago

‘Dawn of oral therapy’: Morphic touts UC data in march toward Takeda’s Entyvio

3 years ago

Updated: Novartis trims pipeline by 10% as Vas Narasimhan places premium on 'high-value medicines'

3 years ago

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

3 years ago

Florida-based biotech with approved cardiovascular therapy moves to go public via SPAC

3 years ago

Boehringer Ingelheim kicks off €350M R&D center in Germany

3 years ago

First page Previous page 89 90 919293 94 95 Next page Last page